NCT00541307

GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)

Post Marketing Study of the GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease (VIPER)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 119 (actual)
• Sponsor: W.L.Gore & Associates · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.

Conditions

• Peripheral Vascular Diseases

Interventions

Type	Name	Description
DEVICE	Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface	Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface

Timeline

• Start date: 2007-10-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2007-10-10
• Last updated: 2012-12-27
• Results posted: 2012-12-27

Locations

5 sites across 1 country: United States